Evidence map›Paper›PMID 42850216›Full record

ArticleCell death discovery2026

p53 wild-type/low c-Myc-expressing ONS76 pediatric medulloblastoma cells become senescent after gamma-irradiation and can be eliminated by senolytic substances.

Jessica Sonntag, Ronja-Linda Preugschas, Danny Jazmati, Nan Qin, Judith Neuwahl, Christiane Matuschek, Marc Remke, Wilfried Budach, Juliane Hörner-Rieber, Dennis Sohn

Abstract read
PubMed Publisher
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jessica Sonntag *Laboratory of Molecular Radiooncology, Clinic and Policlinic for Radiation Therapy and Radiooncology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Ronja-Linda Preugschas *Laboratory of Molecular Radiooncology, Clinic and Policlinic for Radiation Therapy and Radiooncology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Danny JazmatiLaboratory of Molecular Radiooncology, Clinic and Policlinic for Radiation Therapy and Radiooncology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Nan QinDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Judith NeuwahlLaboratory of Molecular Radiooncology, Clinic and Policlinic for Radiation Therapy and Radiooncology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Christiane MatuschekDepartment of Radiation Oncology, Medical School and University, Medical Center OWL, Klinikum Mitte, Bielefeld University, Bielefeld, Germany.
Marc RemkeDepartment of Pediatric Oncology and Hematology, Saarland University, Medical Center, Homburg, Germany.ORCID http://orcid.org/0000-0002-9404-9993
Wilfried BudachClinic and Policlinic for Radiation Therapy and Radiooncology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Juliane Hörner-RieberLaboratory of Molecular Radiooncology, Clinic and Policlinic for Radiation Therapy and Radiooncology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Dennis SohnLaboratory of Molecular Radiooncology, Clinic and Policlinic for Radiation Therapy and Radiooncology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany. dennis.sohn@hhu.de.ORCID http://orcid.org/0009-0004-1392-9609

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Craniospinal irradiation (CSI) is an indispensable part of oncological treatment for pediatric medulloblastoma. However, despite significantly improving oncological outcome, it is also associated with severe short- and long-term side effects such as inflammation and impaired neurocognition. The presence of senescent cells has been identified as a potential contributing factor to these issues. In our study, we demonstrate that p53 wild-type and c-Myc-low-expressing ONS76 medulloblastoma cells underwent senescence, a terminal and stable cell cycle arrest, after exposure to gamma irradiation (γIR). In contrast, p53-mutated UW228-3 cells exhibited apoptosis following the same treatment. ONS76 cells displayed typical senescence properties, including cell and nuclei enlargement, an active DNA damage response with stabilization of p53 and increased expression of its target gene, the CDK inhibitor p21

Identifiers

PMID42850216

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.